利德曼 reported revenue of ¥0.15B for the period ended 2026-06-30, -5.3% year on year. Net income was ¥-0.01B, a -4.9% net margin on a 43.4% gross margin. The largest revenue line is 体外诊断试剂 at 73% of the total. Free cash flow for the period was ¥-0.00B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.15B | -5.3% |
| Gross profit | ¥0.07B | — |
| Operating income | ¥-0.01B | — |
| Net income | ¥-0.01B | — |
| Gross margin | 43.4% | Net margin -4.9% |
| Revenue Q/Q | +15.7% | — |
| Segment | Revenue | Share |
|---|---|---|
| 体外诊断试剂 | ¥0.11B | 72.8% |
| 诊断仪器 | ¥0.02B | 11.3% |
| 其他(补充) | ¥0.02B | 11.3% |
| 生物化学原料 | ¥0.01B | 4.5% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.09B | 56.6% |
| R&D | ¥0.01B | 6.7% |
| SG&A | ¥0.07B | 43.4% |
| Tax & other | ¥0.00B | 0.6% |
| Item | Amount |
|---|---|
| Total assets | ¥1.76B |
| Total liabilities | ¥0.09B |
| Shareholders' equity | ¥1.66B |
| Equity / assets | 94.8% |
| Operating cash flow | ¥0.00B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.00B |
| Cash conversion (OCF / net income) | -124% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
ST荣科 ・ 百纳千成 ・ 吴通控股 ・ 蓝英装备 ・ 博雅生物 ・ *ST三六五 ・ 利亚德 ・ 三诺生物 ・ 富春股份 ・ 海峡创新 ・ ST长方 ・ 同有科技
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies